Literature DB >> 22754594

Heat shock protein 90 inhibition: rationale and clinical potential.

Robert B Den1, Bo Lu.   

Abstract

Heat shock protein 90 (HSP90) is a molecular chaperone protein essential for cellular survival. Functionally, HSPs promote proper protein folding, prevent misfolding, and restore three-dimensional protein structure which is critical following toxic cellular stresses. Recently, targeting HSP90 pharmacologically has gained traction in cancer therapy. Oncogenic cells depend on their ability to withstand endogenous (anoxia, nutrient deprivation, pH changes, and deranged signaling pathways) and exogenous (chemotherapy and radiation therapy) stressors for survival. Pharmacological inhibition of HSP90 destabilizes proteins and leads to degradation through the proteasome. This article will review the utility of HSP90 inhibition, as well as the current adoption in clinical trials and practice.

Entities:  

Keywords:  clinical trial; heat shock protein 90; pharmacological inhibition

Year:  2012        PMID: 22754594      PMCID: PMC3384095          DOI: 10.1177/1758834012445574

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN: 1758-8340            Impact factor:   8.168


  54 in total

1.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

Authors:  Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stanley Kaye; Paul Workman; Ian Judson
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

2.  Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.

Authors:  Sofia Barluenga; Cuihua Wang; Jean-Gonzague Fontaine; Kaïss Aouadi; Kristin Beebe; Shinji Tsutsumi; Len Neckers; Nicolas Winssinger
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

3.  Discovery of the heat shock response.

Authors:  F Ritossa
Journal:  Cell Stress Chaperones       Date:  1996-06       Impact factor: 3.667

4.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors:  Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

5.  89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

Authors:  Wouter B Nagengast; Maarten A de Korte; Thijs H Oude Munnink; Hetty Timmer-Bosscha; Wifred F den Dunnen; Harry Hollema; Johan R de Jong; Michael R Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Guus A M S van Dongen; Marjolijn N Lub-de Hooge; Carolien P Schröder; Elisabeth G E de Vries
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

Review 6.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

7.  A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

Authors:  Arun Rajan; Ronan J Kelly; Jane B Trepel; Yeong Sang Kim; Sylvia V Alarcon; Shivaani Kummar; Martin Gutierrez; Sonja Crandon; Wadih M Zein; Lokesh Jain; Baskar Mannargudi; William D Figg; Brett E Houk; Michael Shnaidman; Nicoletta Brega; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

8.  Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

Authors:  Paul A Brough; Xavier Barril; Jenifer Borgognoni; Patrick Chene; Nicholas G M Davies; Ben Davis; Martin J Drysdale; Brian Dymock; Suzanne A Eccles; Carlos Garcia-Echeverria; Christophe Fromont; Angela Hayes; Roderick E Hubbard; Allan M Jordan; Michael Rugaard Jensen; Andrew Massey; Angela Merrett; Antony Padfield; Rachel Parsons; Thomas Radimerski; Florence I Raynaud; Alan Robertson; Stephen D Roughley; Joseph Schoepfer; Heather Simmonite; Swee Y Sharp; Allan Surgenor; Melanie Valenti; Steven Walls; Paul Webb; Mike Wood; Paul Workman; Lisa Wright
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  Clinical and biological significance of HSP89 alpha in human breast cancer.

Authors:  A Jameel; R A Skilton; T A Campbell; S K Chander; R C Coombes; Y A Luqmani
Journal:  Int J Cancer       Date:  1992-02-01       Impact factor: 7.396

Review 10.  Heat shock protein 90: the cancer chaperone.

Authors:  Len Neckers
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

View more
  16 in total

Review 1.  HSP90AB1: Helping the good and the bad.

Authors:  Michael Haase; Guido Fitze
Journal:  Gene       Date:  2015-09-07       Impact factor: 3.688

2.  Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.

Authors:  Kaijun Di; Stephen T Keir; Daniela Alexandru-Abrams; Xing Gong; Howard Nguyen; Henry S Friedman; Daniela A Bota
Journal:  J Neurooncol       Date:  2014-08-13       Impact factor: 4.130

Review 3.  Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Authors:  Citra Dewi; Adryan Fristiohady; Riezki Amalia; Nur Kusaira Khairul Ikram; Sugeng Ibrahim; Muchtaridi Muchtaridi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

4.  Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.

Authors:  Atul D Joshi; Nektarios Barabutis; Charalampos Birmpas; Christiana Dimitropoulou; Gagan Thangjam; Mary Cherian-Shaw; John Dennison; John D Catravas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-23       Impact factor: 5.464

Review 5.  Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.

Authors:  Ales Vicha; Zdenek Musil; Karel Pacak
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-06       Impact factor: 3.243

6.  Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas.

Authors:  Anupama Singh; Ashok Singh; Jordan M Sand; Samuel J Bauer; Bilal Bin Hafeez; Louise Meske; Ajit K Verma
Journal:  J Invest Dermatol       Date:  2014-10-22       Impact factor: 8.551

7.  Transferrin Modified GSH Sensitive Hyaluronic Acid Derivative Micelle to Deliver HSP90 Inhibitors to Enhance the Therapeutic Efficacy of Brain Cancers.

Authors:  Tilahun Ayane Debele; Ping-Ching Wu; Yu-Feng Wei; Jian-Ying Chuang; Kwang-Yu Chang; Jui-Hung Tsai; Wen-Pin Su
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

8.  Heat shock protein 90 (hsp90) expression and breast cancer.

Authors:  Flora Zagouri; Evangelos Bournakis; Konstantinos Koutsoukos; Christos A Papadimitriou
Journal:  Pharmaceuticals (Basel)       Date:  2012-09-12

Review 9.  Promising oncolytic agents for metastatic breast cancer treatment.

Authors:  James J Cody; Douglas R Hurst
Journal:  Oncolytic Virother       Date:  2015-06-03

Review 10.  The wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disorders.

Authors:  Nutan Tyagi; Rishi Tyagi
Journal:  J Oral Maxillofac Pathol       Date:  2015 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.